Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation
Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation
复制标题
DOI：
10.1097/moh.0b013e32834b6158
复制
发表时间：
2011-11-01
影响因子：
3.2
通讯作者：
de Lima, Marcos
中科院分区：
文献类型：
--
作者：
Oran, Betul;de Lima, Marcos
综述目的复发仍然是异基因造血干细胞移植(allo-HCT)治疗急性髓系白血病(AML)患者治疗失败的主要原因。大多数复发的患者将由于治疗效果低、毒性或虚弱问题而死亡。本文综述了预防和治疗移植并发症的临床研究和治疗应用的最新进展。最近的发现几个小组已经证明监测异基因hct后的微小残留病(MRD)是可行的，并可以预测即将到来的血液学复发。新的抗白血病药物在准备方案中的引入，移植后缓解治疗的维持，以及基于MRD的早期治疗干预都有可能改善结果。
Purpose of reviewRelapse remains a major cause of treatment failure for acute myeloid leukemia (AML) patients treated with allogeneic hematopoietic stem cell transplantation (allo-HCT). Most patients that recur will perish due to low treatment efficacy, toxicity, or frailty issues. This review summarizes recent developments in clinical research and therapeutic applications for prevention and treatment of this complication of transplantation.Recent findingsSeveral groups have demonstrated that monitoring minimal residual disease (MRD) after allo-HCT is feasible and is predictive of impending hematologic recurrence. The introduction of novel antileukemia agents in the preparative regimen, maintenance of remission treatment posttransplant, and early MRD-based therapeutic interventions all have the potential to improve outcomes.SummaryInnovative basic and clinical investigation is urgently needed to improve treatment and prevention of AML recurrence after allogeneic transplantation.